Pharsight

1. Delstrigo patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8486975	MSD MERCK CO	Non-nucleoside reverse transcriptase inhibitors	Oct, 2031 (7 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10603282	MSD MERCK CO	Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine	Nov, 2036 (12 years from now)
US10842751	MSD MERCK CO	Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine	Nov, 2036 (12 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Jan 27, 2025
New Chemical Entity Exclusivity(NCE)	Aug 30, 2023
New Indication(I-806)	Sep 19, 2022

Drugs and Companies using DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE ingredient

NCE-1 date: 30 August, 2022

Market Authorisation Date: 30 August, 2018

Treatment: Treatment of hiv-1 infection in pediatric patients weighing at least 35kg with no prior antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically...

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
100 mg/300 mg/ 300 mg	30 Aug, 2022	1		29 Nov, 2036

Strength	Dosage	Availability
100MG;300MG;300MG	TABLET;ORAL	Prescription

DELSTRIGO family patents

2. Emend patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP02796109A	2009-04-06	Hexal AG	Patent maintained as amended
EP02796109A	2009-04-06	Teva Pharmaceutical Industries Ltd.	Patent maintained as amended

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6096742	MSD MERCK CO	Polymorphic form of a tachykinin receptor antagonist	Jul, 2018 (5 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8258132	MSD MERCK CO	Pharmaceutical composition of a tachykinin receptor antagonist	Sep, 2027 (3 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Aug 28, 2018

Drugs and Companies using APREPITANT ingredient

Market Authorisation Date: 17 December, 2015

Treatment: Prevention of nausea and vomiting associated with chemotherapy (cinv)

Dosage: FOR SUSPENSION;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
40 mg, 80 mg and 125 mg	03 Nov, 2008	1	24 Sep, 2012	17 Apr, 2015	Deferred
125 mg/Kit	23 Nov, 2016	1		26 Sep, 2027	Extinguished

Strength	Dosage	Availability
125MG/KIT	FOR SUSPENSION;ORAL	Prescription

EMEND family patents

3. Pifeltro patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8486975	MSD MERCK CO	Non-nucleoside reverse transcriptase inhibitors	Oct, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Jan 27, 2025
New Indication(I-827)	Sep 19, 2022
New Chemical Entity Exclusivity(NCE)	Aug 30, 2023

Drugs and Companies using DORAVIRINE ingredient

NCE-1 date: 30 August, 2022

Market Authorisation Date: 30 August, 2018

Treatment: For use in combination with other antiretroviral agents to treat hiv-1 infection in pediatric patients weighing at least 35kg with no prior antiretroviral treatment history or to replace the current a...

Dosage: TABLET;ORAL

Strength	Dosage	Availability
100MG	TABLET;ORAL	Prescription

PIFELTRO family patents

4. Recarbrio patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8487093	MSD MERCK CO	β-lactamase inhibitors	Nov, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jul 16, 2024
Generating Antibiotic Incentives Now(GAIN)	Jul 16, 2029

Drugs and Companies using CILASTATIN SODIUM; IMIPENEM; RELEBACTAM ingredient

NCE-1 date: 16 July, 2028

Market Authorisation Date: 16 July, 2019

Treatment: Treatment of complicated urinary tract infections, including pyelonephritis (cuti)

Dosage: POWDER;INTRAVENOUS